Cargando…
In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133(high) to CD133(low) phenotype and reduces the CD133-related invasiveness
BACKGROUND: Beyond its possible correlation with stemness of tumor cells, CD133/prominin1 is considered an important marker in breast cancer, since it correlates with tumor size, metastasis and clinical stage of triple-negative breast cancers (TNBC), to date the highest risk breast neoplasia. METHOD...
Autores principales: | Brugnoli, Federica, Grassilli, Silvia, Piazzi, Manuela, Palomba, Maria, Nika, Ervin, Bavelloni, Alberto, Capitani, Silvano, Bertagnolo, Valeria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866498/ https://www.ncbi.nlm.nih.gov/pubmed/24330829 http://dx.doi.org/10.1186/1476-4598-12-165 |
Ejemplares similares
-
CD133 in Breast Cancer Cells: More than a Stem Cell Marker
por: Brugnoli, Federica, et al.
Publicado: (2019) -
Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133(+)/EpCAM(+) phenotype: a promising target for preventing progression of TNBC
por: Brugnoli, Federica, et al.
Publicado: (2017) -
Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010) -
Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018) -
Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations
por: Grasso, Carole, et al.
Publicado: (2016)